ALSP

KLDiscovery Investments Lead to a Record-Breaking Year in 2023

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Professional Services, Legal, Technology, Software, CLM, Organization, Software as a service, Growth, Intelligence, Education, RAID, Warner Bros. Discovery EMEA, Blog, Acquisition, RSMF, ALSP, OnTrack, Investment, Contract lifecycle management, Data management, Collection, Engineering

With continued investments in its operations, KLDiscovery delivered impressive statistics in 2023, showcasing the Company’s reputation as the trusted partner of choice for supporting large and complex matters.

Key Points: 
  • With continued investments in its operations, KLDiscovery delivered impressive statistics in 2023, showcasing the Company’s reputation as the trusted partner of choice for supporting large and complex matters.
  • The Company also made sizable investments in innovative programs enabling organizations to partner with KLDiscovery in multiple ways.
  • "Our achievements in 2023 are a testament to our team's hard work, innovation, and dedication to excellence," said Chris Weiler, CEO of KLDiscovery.
  • To learn more about KLDiscovery’s investments and achievements in 2023, please visit the Company’s blog .

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
Microglia, American Academy, American Academy of Neurology, ALSP, AAN, Poster

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.

Key Points: 
  • WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced one oral and two poster presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting taking place on April 13-18, 2024 in Denver, Colorado and virtually.
  • Details of the oral presentation are as follows:
    Title: Interim Results on VGL101 From IGNITE: First Interventional Phase 2 Study in Patients with Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
    Details of the poster presentations are as follows:
    Presented by: David S. Lynch, M.D., Ph.D., National Hospital for Neurology & Neurosurgery; University College London Institute of Neurology

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

Retrieved on: 
Thursday, February 29, 2024
CSF1R, ALSP, Genetic testing, Approximation error, Neurodegenerative disease, Life, Multiple sclerosis, Patient, Disease, Senior counsel, Diagnosis, Microglia, Research, Medical device

WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) --  Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented a poster detailing the impact of misdiagnosis and the importance of genetic testing at the 2024 ACTRIMS Forum being held in West Palm Beach, Florida, from February 29 – March 2.

Key Points: 
  • “We continue to hear from members of the ALSP community that the path to an accurate diagnosis can be difficult, indirect, and time consuming.
  • As with many rare diseases, the misdiagnosis of ALSP can be a significant and persistent challenge to overcome.
  • It also showed that when considering genetic testing, access to approved treatments may be a motivator for patients, family members, and clinicians.
  • A structured patient journey workshop was hosted as a means of better understanding life with ALSP, including the impact of misdiagnosis and barriers to genetic testing.

Relativity Announces its Third Annual AI Visionaries List

Retrieved on: 
Monday, January 22, 2024
Fortune 500, ALSP, CIO, Bayer Corporation, BakerHostetler, AI

CHICAGO, Jan. 22, 2024 /PRNewswire/ -- Relativity, a global legal technology company, today announced its annual list of AI Visionaries. The list recognizes and celebrates individuals who have explored, promoted or experimented with AI in novel ways in legal applications.

Key Points: 
  • CHICAGO, Jan. 22, 2024 /PRNewswire/ -- Relativity , a global legal technology company, today announced its annual list of AI Visionaries .
  • The list recognizes and celebrates individuals who have explored, promoted or experimented with AI in novel ways in legal applications.
  • The AI Visionaries' accomplishments have laid the groundwork for an inspirational, AI-fueled future, and we look forward to celebrating them."
  • Spotlighting leaders from Fortune 500 companies and top Am Law firms, the 2024 AI Visionaries list features those who have experimented with AI technologies prior to recent increased industry adoption and encouraged the use of AI both within their organization and outside of it.

Relativity Announces its Third Annual AI Visionaries List

Retrieved on: 
Monday, January 22, 2024
Fortune 500, ALSP, CIO, Bayer Corporation, BakerHostetler, AI

CHICAGO, Jan. 22, 2024 /PRNewswire/ -- Relativity, a global legal technology company, today announced its annual list of AI Visionaries. The list recognizes and celebrates individuals who have explored, promoted or experimented with AI in novel ways in legal applications.

Key Points: 
  • CHICAGO, Jan. 22, 2024 /PRNewswire/ -- Relativity , a global legal technology company, today announced its annual list of AI Visionaries .
  • The list recognizes and celebrates individuals who have explored, promoted or experimented with AI in novel ways in legal applications.
  • The AI Visionaries' accomplishments have laid the groundwork for an inspirational, AI-fueled future, and we look forward to celebrating them."
  • Spotlighting leaders from Fortune 500 companies and top Am Law firms, the 2024 AI Visionaries list features those who have experimented with AI technologies prior to recent increased industry adoption and encouraged the use of AI both within their organization and outside of it.

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

Retrieved on: 
Thursday, November 16, 2023
Safety, Magnetic resonance imaging, Pathology, Disease, Clinical trial, TREM2, Patient, Medicine, FDA, Microglia, Caregiver, NHS England, Neurodegenerative disease, Osteopontin, Mayo Clinic, MRI, Biomarker, UCL Institute of Ophthalmology, IGNITE, HIV disease progression rates, AFL, Dietary supplement, Medical imaging, Communications satellite, Pharmaceutical industry, Vigil, CSF1R, Neurology, ALSP

"The positive interim results from our Phase 2 IGNITE trial represent the first clinical data reported from an interventional study in patients with ALSP and reaffirm our belief in the potential of iluzanebart as a novel treatment option.

Key Points: 
  • "The positive interim results from our Phase 2 IGNITE trial represent the first clinical data reported from an interventional study in patients with ALSP and reaffirm our belief in the potential of iluzanebart as a novel treatment option.
  • Key Highlights from Phase 2 IGNITE Interim Data:
    Favorable safety and tolerability profile, including no hematologic adverse events.
  • We believe the quality and consistency of the interim data further support the continuation of IGNITE without modification.
  • Interim Montreal Cognitive Assessment (MoCA) and Cortical Basal Ganglia Functional Scale data support use as clinical endpoints in ALSP at 12 months.

Integreon Looks to Disrupt $20 billion Industry and Becomes the First Generative AI-Led ALSP with Leah Legal Copilot by ContractPodAi

Retrieved on: 
Tuesday, December 5, 2023
Legal, Technology, Business, Professional Services, Software, Internet, Data Analytics, Data Management, Artificial Intelligence, LLM Communications, ROI, Private law, Orangi Pilot Project, CLM, AI, ALSP, Management

As a result, Integreon is now the first alternative legal services provider (ALSP) to adopt a fully generative AI-led approach.

Key Points: 
  • As a result, Integreon is now the first alternative legal services provider (ALSP) to adopt a fully generative AI-led approach.
  • Over the last two years, ALSPs have grown by 45% into a $20.6 billion industry, primed for innovation.
  • With Leah, Integreon clients will benefit from generative AI and its ability to streamline services and deliver even more efficiency.
  • “This is a game-changer, and it represents that Leah and Integreon are taking the ALSP delivery model to the future.

KLDiscovery Inc. Completes Acquisition of Cenza Technologies Private Limited

Retrieved on: 
Monday, November 20, 2023
Legal, Software, Data Analytics, Consulting, Artificial Intelligence, Data Management, Professional Services, Technology, Acquisition, Legal technology, Partner, Contract lifecycle management, Private law, Partnership, CLM, ALSP, Management

KLDiscovery Inc. (“KLD”), a leading global provider of electronic discovery, information governance, and data recovery services, today announced the closing of their previously announced acquisition of the business of Cenza Technologies Private Limited (“Cenza”), an India-based alternative legal services provider (“ALSP”) that offers Contract Lifecycle Management (“CLM”) and CLM implementation services, document review, and LawTech and legal AI driven solutions.

Key Points: 
  • KLDiscovery Inc. (“KLD”), a leading global provider of electronic discovery, information governance, and data recovery services, today announced the closing of their previously announced acquisition of the business of Cenza Technologies Private Limited (“Cenza”), an India-based alternative legal services provider (“ALSP”) that offers Contract Lifecycle Management (“CLM”) and CLM implementation services, document review, and LawTech and legal AI driven solutions.
  • “We are thrilled to finally welcome the talented Cenza team into the KLDiscovery family,” said Christopher Weiler, CEO of KLDiscovery.
  • “Throughout the past few weeks, we have collaborated closely with the Cenza team to complete the acquisition.
  • “This is an exciting new chapter for both Cenza and KLDiscovery,” said Aditya Mirza, CEO of Cenza.

ALSP Orchid Acquisition Corporation I Announces it Will Redeem its Public Shares and Will Not Consummate an Initial Business Combination

Retrieved on: 
Wednesday, November 8, 2023
Science, Venture Capital, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Transfer, IPO, Commission, Tax, Accounting, Form S-1, Form, Wind, Electric Bond and Share Company v. Securities and Exchange Commission, Bank statement, Finance Secretary (India), Trust, Interest on Lawyer Trust Accounts, Extension, ALSP, Articles of association, Security (finance), Article

As stated in the Company’s Articles and in the Company’s registration statement on Form S-1 (Registration No.

Key Points: 
  • As stated in the Company’s Articles and in the Company’s registration statement on Form S-1 (Registration No.
  • The per-share redemption price for the Public Shares will be approximately $10.86 (the “Redemption Amount”).
  • The Redemption Amount will be payable to the holders of the Public Shares upon delivery of their shares or units to the Company’s transfer agent, Continental Stock Transfer & Trust Company.
  • Beneficial owners of Public Shares held in “street name,” however, will not need to take any action in order to receive the Redemption Amount.

Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023
FDA, Research, Data analysis, Research and development, AD, IGNITE, Half-life, Genetic testing, Event, Food, European Commission, Publication, European Medicines Agency, Microglia, CSF1R, MAD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SAD, R, HCP, ANA, Approximation error, Civil service commission, Growth, Caregiver, PK, KOL, Medicine, EMA, TREM2, Patient, Administration, Investigational New Drug, Pharmaceutical industry, Cryptocurrency, IND, ALSP

WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2023, and provided an update on recent progress.

Key Points: 
  • In September, we also proudly introduced our oral small molecule TREM2 agonist candidate, VG-3927, with the opening of our IND.
  • Cash Position: Cash, cash equivalents, and marketable securities were $133.6 million as of September 30, 2023, compared to $150.2 million as of June 30, 2023.
  • General and Administrative (G&A) Expenses: G&A expenses for the third quarter ended September 30, 2023, were $6.9 million, compared to $4.8 million for the same period in 2022.
  • Net Loss: Loss from operations for the third quarter ended September 30, 2023, were $20.5 million, compared to $17.5 million for the same period in 2022.